Associate Professor, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai
Eirini Papapetrou obtained MD and PhD degrees from the University of Patras in Greece and did postdoctoral research in genetic engineering and stem cell biology with Michel Sadelain at Memorial Sloan-Kettering Cancer Center. There she was one of the first investigators to derive patient-specific induced pluripotent stem cells (iPSCs) and use them in disease modeling and regenerative medicine applications. As an independent investigator, first at the University of Washington in Seattle and, since 2014, at the Icahn School of Medicine at Mount Sinai in New York, she developed the first iPSC models of myeloid malignancies, in particular Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Her lab harnesses somatic cell reprogramming, CRISPR genome editing and human pluripotent stem cell-derived hematopoiesis to develop novel iPSC-based models of MDS and AML for genotype-to-phenotype studies, interrogation of disease mechanisms and genetic and small molecule screens with the goal to understand disease mechanisms, identify new therapeutic targets and repurpose drugs.
Dr. Papapetrou is the recipient of several awards, including the American Society of Gene and Cell Therapy (ASGCT) Outstanding New investigator Award, Damon Runyon-Rachleff Innovation Award, American Society for Clinical Investigation (ASCI) Young Physician-Scientist Award, Sidney Kimmel Foundation Scholar Award, American Society of Hematology (ASH) Scholar Award, Ellison Medical Foundation New Scholar Award, Leukemia & Lymphoma Society (LLS) Scholar Award and Pershing Square Sohn Prize.